Prof. Yaron Niv, MD, FACG, AGAF
Director of Gastroenterology Department
Director of Quality and Risk Management Department
Deputy Director, Rabin Medical Center
Prof. Yaron Niv, MD, FACG, AGAF
Director of Gastroenterology Department
Director of Quality and Risk Management Department
Deputy Director, Rabin Medical Center
Education
1969-1975 Sackler Faculty of Medicine, Tel Aviv University
1976 MD Degree
1983 Board Certified Gastroenterology – Israel Scientific Council
1988-1989 Research Fellowship – GI oncology – UCSF, San Francisco, USA
2000 Jackson Memorial Medical Center, Miami – Small bowel transplantation
2004 Baylor University Medical Center, Dallas – HNPCC, JCV and CRC
Academic and other positions
Full clinical Professor of medicine, Sackler Faculty of medicine
Chairman of the Section of Gastrointestinal Oncology of the Israeli Association of Gastroenterology, and Past President IGA
Corresponding Fellow European Helicobacter Study Group
Visiting Professor UCSD (2011)
Editorial Board: IMAJ, Gut and Liver, WJG, Clin and Experimental GE
Research areas
Our primary research is about colorectal cancer from every clinical or basic science aspects. We look at epidemiology, clinical presentation, sporadic and hereditary forms of the disease (HNPCC, FAP etc.), genetic changes, and the association between inflammation and carcinogenesis. Recently we investigated the possible association between different mucin genes expression and colorectal cancer survival and metastatic potential in human and in mice model.
Publications (2009-2012):
Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E, Birkenfeld S, Lieberman N, Klang S, Niv Y.Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulants.Am J Gastroenterol 2009; 104:933-8.
Rozen P, Levi Z, Hazazi R, Waked A, Vilkin A, Maoz E, Birkenfeld S, Leshno M, Niv Y. Identification of colorectal adenomas by a quantitative immunochemical fecal occult blood screening test depends on adenoma characteristics. Development threshold used and number tests performed. Aliment Pharmacol Ther 2009; 15:29:906-17.
Vilkin A, Niv Y, Nagasaka T, Morgenstern S, Levi Z, Fireman Z, Fuerst F, Goel A, Boland CR. Microsatelite instability, MKH1 promoter hyper methylation, and BRAF mutation analysis in sporadic colorectal cancers of different ethnic groups in Israel. Cancer 2009; 115:760-9.
Rozen P, Levi Z, Hazazi R, Waked A, Vilkin A, Maoz E, Birkenfeld S, Niv Y. Quantitative colonoscopic evaluation of relative efficiencies of animmunochemical fecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasm. Aliment Pharmacol Ther 2009; 15;29:450-7.
Zvidi I, Hazazi R, Birkenfeld S, Niv Y. The prevalence of Crohn's disease in Israel, a twenty-year survey. Dig Dis Sci 2009;54:848-52.
Vilkin A, Geller A, Levi Z, Niv Y. Mucin expression in bile collected by ERCP in 29 consecutive cases. WJG 2009;15:2367-2371.
Birkenfeld S, Zvidi I, Hazazi R, Niv Y. The prevalence of ulcerative colitis in Israel, a twenty-year survey. J Clin Gastroenterol 2009;43:743-746.
Levi Z, Fraser E, Krongard R, Hazazi R, Benjaminov O, Meyerovitch J, Tal OB, Choen A, Niv Y, Fraser G. Factors associated with radiation exposure in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009; 30:1128-36.
Eliakim R, Yassin K, Niv Y, Lachter J, Gal E et al. PillCam Colon 2, second generation capsule endoscopy – results of the first prospective multicenter trial. Endoscopy 2009;41:1026-1031.
Ladas SD, Triantafyllou K, Spada C, Riccioni ME, Rey JF, Niv Y, Delvaux M, de Franchis R, Costamagna G. European guidelines of capsule endoscopy. endoscopy – Non-stricturing small bowel Crohn's disease. Endoscopy 2010;42:220-227.
Hazazi R, Rozen P, Leshno M, Levi Z, Samuel Z, Waked A, Vilkin A, Maoz E, Birkenfeld S, Niv Y. Can patients at high-risk for significant colorectal neoplasm and having normal quantitative fecal occult blood test postpone elective colonoscopy? Aliment Pharmacol Ther 2010;31:523-533.
Dickman R, Levi Z, Vilkin A, Zvidi I, Niv Y. Predictors of specialized intestinal metaplasia in patients with an Incidental irregular Z line. EJGH 2010; 22:135-138.
Rozen P, Comaneshter D, Levi Z, Hazazi R, Waked A, Vilkin A, Maoz E, Birkenfeld S, Niv Y.
Cumulative evaluation of quantitative immunochemicall fecal occult blood test to determine optimal clinical use. Cancer 2010;116:2115-2125.
Cohen M, Niv Y. Appropriateness of GI consultations for hospitalized patients in an academic medical center. J Postgarduate Med 2010;56:17-20.
Groshar D, Sosna J, Bernstein H, Niv Y, Fraser G..PET/CT enterography in Crohn's disease: comparison of CT enterography findings with 18F-FDG uptake. J Nuc Med 2010;51:1009-1014
Niv Y, Vilkin A, Levi Z, Kundel Y, Brenner B, Morgenstern S. MLH1 promoter methylation and JC virus T Ag presence in the tumor tissue of colorectal cancer Israeli patients of different ethnic groups. EJGH 2010;22:938-941.
Niv Y, Vilkin A, Levi Z. Patients with sporadic CRC or AAP have elevated anti-JCV antibody titer in comparison with healthy controls: a cross sectional study. J Clin Gastroenterol 2010;44:489-494.
Boltin D, Vilkin A, Levi Z, Elkayam O, Niv Y. JC virus T-Antigen in gastrointestinal mucosa of immunosuppressed patients – a prospective, controlled study. Dig Dis Sci 2010;55:1975-1981.
Levinson-Castiel R, Hartman C, Morgenstern S, Avitzur Y, Hirsch A, Rosenbach Y, Shapiro R, Zevitt N, Fleischaker H, Niv Y, Shamir R. The role of duodenal biopsy in diagnosis of celiac disease in children. Clin Gastroenterol 2011;45:26-29.
Levi Z, Vilkin A, Rozen P, Hazazi R, Waked A, Maoz E, Birkenfeld S, Liberman N, Klang S, Niv Y. Esophago-gastro-duodenoscopy is not indicated in Patients with Positive Immunochemical Test and Non Explanatory Colonoscopy. EJGH 2010; 22:1431-1434.
Niv Y. Helicobacter pylori/NSAID – negative peptic ulcer – the mucin theory. Medical Hypothesis 2010;75:433-435.
Vernick S, Freeman A, Rishpon J, Niv Y, Shacham-Diamand Y. Electromechanical biosensing direct biopsy slices screening for CRC detection. J Electrochem Soc 2011;158:1-4.
Zevit N, Levi Z, Shirin H, Niv Y, Shamir R. Age and gender differences in 13C-UBT results. Eur J Clin Invest 2011; 41:767-772.
Dickman R, Steinmetz A, Bernnstine H, Groshar D, Niv Y. A novel continuous breath test versus scintigraphy for gastric emptying rate measurments. J Clin Gastroenterol 2011; 45:22-25.
Niv Y, gershtanski Y, Tal Y, Kennet R, Birkenfeld S. Analysis of 7-year physician-reported adverse events in ERCP and EUS. Drug Health Care and Patient Safety 2011;3:21-25.
Dickman R et al.Perception of gastroenterologists and nurses regarding IBS and IBD. EJGH 2011;23:813-817.
Niv Y, gershtanski Y, Tal Y, Kennet R, Birkenfeld S. Analysis of 7-year physician-reported adverse events in colonoscopy. Eur J Gastro Hepathol 2011;23:492-498
Schmiloviz-Weiss H, Shalev T, Chechoulin Y, Levi Z, Yishai R, Sehayek-Shabbat V, Niv Y, Shirin H. High eradication rates of Helicobacter pylori infection following sequential therapy: the Israeli experience treating naïve patients. Helicobacter 2011;16:229-233.
Levi Z, Gal E, Vilkin A, Chonen Y, Gingold Belfer R, Fraser G, Niv Y. Fecal immunochemical test and small bowel lesions detected on capsule endoscopy: results of a prospective study in patients with obscure occult gastrointestinal bleeding. Eur J Gastroenterol Hepatol 2011;23:1024-1028.
Levi Z et al. Measured body mass index in adolescence and the incidence of colo-rectal cancer in a cohort of 1.1 million males. Cancer Epidemiology, Biomarkers & Prevention 2011 Nov 4.
Dickman R, Boaz M, Aizic S, Beniashvili Z, Fass R, Niv Y. Comparison of clinical characteristics of patients with GERD who failed PPI therapy versus those who fully responded. J Neurogastroenterol Motil 2011;17:387-94.
Agréus Lars et al. Atrophic gastritis is a poorly recognized risk condition for gastric cancer.Plasma biomarkers are a noninvasive tool for its diagnosis. Scand J gastroenterol 2012;47:136-47.
Brenner B, Hoshen MB, Purim O, David MB, Ashkenazi K, Marshak G, Kundel Y, Brenner R, Morgenstern S, Halpern M, Rosenfeld N, Chajut A, Niv Y, Kushnir M. MicroRNAs as a potential prognostic factor in gastric cancer. World J Gastroenterol 2011;17:3976-3985.
Rokkas T and Niv Y. The role of video capsule endoscopy in the diagnosis of celiac disease: a meta-analysis. Eur J Gastro hep 2012;24:303-308.
Weiss H et al. Does a colonoscopy following acute diverticulitis affect its management – a single center experience. J Clinic Gastro 2012;46:317-320.
Levi Z et al. Measured body mass index in adolescence and the incidence of Pancreatic cancer in a cohort of 720,000 million men. Cancer Causes Control 2012;23:371-378.
Niv Y, gershtanski Y, Tal Y, Kennet R, Birkenfeld S. Analysis of 7-year physician-reported adverse events in EGD. J Patient Safety 2012;8:65-68.
Niv Y et al.Validation of Capsule Endoscopy Crohn's Disease Activity Score (CECDAI or Niv Score) - A multi center prospective study. Endoscopy 2012;44:21-26.
Niv et al. Impact of colonoscopy on quality of life. Eur J Gastro Hep 2012;24:781-786.
Weissmann-Brenner A et al.Tumor micro-RNA-29a expression and the risk of recurrence in stage II colon cancer. Int J Oncol 2012;40:2097-2103.
Zevit N et al. Inverse association between Helicobacter pylori and pediatric asthma in high-prevalence population. Helicobacter 2012;17:30-35.